Benchmark Maintains Buy on Getty Images Holdings, Lowers Price Target to $7
Benchmark analyst Mark Zgutowicz maintains Getty Images Holdings (NYSE:GETY) with a Buy and lowers the price target from $9 to $7.
Oppenheimer Maintains Outperform on Seagen, Raises Price Target to $229
Oppenheimer analyst Jay Olson maintains Seagen (NASDAQ:SGEN) with a Outperform and raises the price target from $210 to $229.
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $20
Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and raises the price target from $19 to $20.
Stephens & Co. Reiterates Overweight on Avid Bioservices, Maintains $22 Price Target
Stephens & Co. analyst Jacob Johnson reiterates Avid Bioservices (NASDAQ:CDMO) with a Overweight and maintains $22 price target.
Stephens & Co. Reiterates Equal-Weight on Amedisys, Maintains $103 Price Target
Stephens & Co. analyst Scott Fidel reiterates Amedisys (NASDAQ:AMED) with a Equal-Weight and maintains $103 price target.
RBC Capital Reiterates Outperform on Viracta Therapeutics, Maintains $8 Price Target
RBC Capital analyst Gregory Renza reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $8 price target.
Goldman Sachs Maintains Buy on Charles Schwab, Lowers Price Target to $75
Goldman Sachs analyst Alexander Blostein maintains Charles Schwab (NYSE:SCHW) with a Buy and lowers the price target from $98 to $75.
RBC Capital Reiterates Sector Perform on Paysafe, Maintains $36 Price Target
RBC Capital analyst Daniel Perlin reiterates Paysafe (NYSE:PSFE) with a Sector Perform and maintains $36 price target.
RBC Capital Reiterates Sector Perform on BioCryst Pharma, Maintains $10 Price Target
RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:BCRX) with a Sector Perform and maintains $10 price target.
JMP Securities Reiterates Market Outperform on Vacasa, Maintains $3 Price Target
JMP Securities analyst Eric Ross reiterates Vacasa (NASDAQ:VCSA) with a Market Outperform and maintains $3 price target.